These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 12640212)

  • 21. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients.
    Perry PJ; Sanger T; Beasley C
    J Clin Psychopharmacol; 1997 Dec; 17(6):472-7. PubMed ID: 9408810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine.
    Zullino DF; Delessert D; Eap CB; Preisig M; Baumann P
    Int Clin Psychopharmacol; 2002 May; 17(3):141-3. PubMed ID: 11981356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
    Mihara K; Suzuki A; Kondo T; Yasui N; Furukori H; Nagashima U; Ono S; Kaneko S; Otani K; Inoue Y
    Ther Drug Monit; 2000 Jun; 22(3):245-9. PubMed ID: 10850389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration.
    Markowitz JS; DeVane CL
    J Clin Psychopharmacol; 1999 Jun; 19(3):289-91. PubMed ID: 10350045
    [No Abstract]   [Full Text] [Related]  

  • 25. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.
    Lind AB; Reis M; Bengtsson F; Jonzier-Perey M; Powell Golay K; Ahlner J; Baumann P; Dahl ML
    Clin Pharmacokinet; 2009; 48(1):63-70. PubMed ID: 19071885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement.
    van der Weide J; Steijns LS; van Weelden MJ
    Pharmacogenetics; 2003 Mar; 13(3):169-72. PubMed ID: 12618594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial.
    Perry PJ; Lund BC; Sanger T; Beasley C
    J Clin Psychopharmacol; 2001 Feb; 21(1):14-20. PubMed ID: 11199942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients.
    Melkersson KI; Scordo MG; Gunes A; Dahl ML
    J Clin Psychiatry; 2007 May; 68(5):697-704. PubMed ID: 17503978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia.
    Bozikas VP; Papakosta M; Niopas I; Karavatos A; Mirtsou-Fidani V
    Eur Neuropsychopharmacol; 2004 Jan; 14(1):39-44. PubMed ID: 14659985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects.
    Miroshnichenko II; Pozhidaev IV; Ivanova SA; Baymeeva NV
    Ther Drug Monit; 2020 Apr; 42(2):325-329. PubMed ID: 31425442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia.
    Ellingrod VL; Perry PJ; Lund BC; Bever-Stille K; Fleming F; Holman TL; Miller D
    J Clin Psychopharmacol; 2002 Dec; 22(6):622-4. PubMed ID: 12454564
    [No Abstract]   [Full Text] [Related]  

  • 32. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene.
    Eap CB; Bender S; Jaquenoud Sirot E; Cucchia G; Jonzier-Perey M; Baumann P; Allorge D; Broly F
    J Clin Psychopharmacol; 2004 Apr; 24(2):214-9. PubMed ID: 15206669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication.
    Olesen OV; Linnet K
    Ther Drug Monit; 1999 Feb; 21(1):87-90. PubMed ID: 10051059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
    Frye RF; Branch RA
    Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication.
    Linnet K; Olesen OV
    Ther Drug Monit; 2002 Aug; 24(4):512-7. PubMed ID: 12142636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C.
    Becquemont L; Chazouilleres O; Serfaty L; Poirier JM; Broly F; Jaillon P; Poupon R; Funck-Brentano C
    Clin Pharmacol Ther; 2002 Jun; 71(6):488-95. PubMed ID: 12087352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.
    Lucas RA; Gilfillan DJ; Bergstrom RF
    Eur J Clin Pharmacol; 1998 Oct; 54(8):639-43. PubMed ID: 9860152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters.
    Lu ML; Lin CH; Chen YC; Yang HC; Wu TH
    PLoS One; 2013; 8(5):e65719. PubMed ID: 23741510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting.
    Skogh E; Reis M; Dahl ML; Lundmark J; Bengtsson F
    Ther Drug Monit; 2002 Aug; 24(4):518-26. PubMed ID: 12142637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.
    Carrillo JA; Dahl ML; Svensson JO; Alm C; Rodríguez I; Bertilsson L
    Clin Pharmacol Ther; 1996 Aug; 60(2):183-90. PubMed ID: 8823236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.